Overview

The Use of Ranolazine for Atrial Fibrillation and Diastolic Heart Failure

Status:
Terminated
Trial end date:
2014-02-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the efficacy of ranolazine in the prevention of recurrent atrial fibrillation in post-cardioversion patients with heart failure and preserved ejection fraction.
Phase:
Phase 2
Details
Lead Sponsor:
Intermountain Health Care, Inc.
Collaborator:
Gilead Sciences
Treatments:
Ranolazine